Belimumab

Belimumab
	Fab fragment of belimumab. PDB: 5Y9K.
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	B-cell activating factor (BAFF, BLyS)
Clinical data
Trade names	Benlysta
Other names	LymphoStat-B
AHFS/Drugs.com	Monograph
MedlinePlus	a611027
License data	US DailyMed: Belimumab;
Pregnancy; category	AU: C;
Routes of; administration	Intravenous, subcutaneous
ATC code	L04AG04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only / Schedule D; US: ℞-only; EU: Rx-only;
Identifiers
CAS Number	356547-88-1 ;
DrugBank	DB08879;
ChemSpider	none;
UNII	73B0K5S26A;
KEGG	D03068 ;
ChEMBL	ChEMBL1789843;
Chemical and physical data
Formula	C6358H9904N1728O2010S44
Molar mass	144121.90 g·mol−1
	(what is this?) (verify)

Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis.

The most common side effects include bacterial infections, such as bronchitis (infection in the lungs) and infection of the urinary tract (structures that produce or carry urine), diarrhea and nausea (feeling sick).